CTX110

DB18626InvestigationalCell transplant therapies

CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

Mechanism
Curator reviewed
Also known as
allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
Code names
CTX-110

Resolves to

Targets
P15391CD19

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with CTX110, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In